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Many studies have supported the role of protein kinase C (PKC) inhibitors in the 
physiopathology and treatment of bipolar disorder in adults. Tamoxifen is one of 
the drugs with the effect of PKC inhibition. This study aimed to determine the 
effect of tamoxifen on the rate of improvement mania symptoms in the sample 
of children and adolescents with acute mania.
Materials & Methods
In this randomized, placebo-controlled clinical trial study, registered in
www.irct.ir with the code of IRCT201410126418N3, overall 44 patients 
with bipolar disorder with acute manic episode were randomly assigned into 
treatment and control groups. The serum levels of lithium and tamoxifen among 
the participants in the treatment groups were 0.8 -1.1 mg and 20-40 mg per day 
respectively. Serum level of lithium among participants in the control group 
was similar. The main comparisons were made based on the Young Mania 
Rating Scale (YMRS) and Children Depression Inventory (CDI) scores of the 
participants at baseline and at the end of each study week. The pharmacological 
side effects of serum level of lithium were examined weekly. Analysis of 
Covariance(ANCOVA) test was used for the statistical analysis.
Results
There was no difference in the baseline score of YMRS and CDI in the treatment 
and control groups while a statistical significant difference (P < 0.05) in these 
scores was found between and within the groups. 
Conclusion
The addition of tamoxifen to lithium causes a significant difference in reducing 
the symptoms of mania and depression in the treatment group compared to the 
control group.
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Introduction
The identification of protein kinase C (PKC) has recently been introduced as a 
promising therapeutic aim. Protein kinase C is a large family of isoenzymes typically 
found in brain and plays a crucial role in settings before and after synapse called 
neurotransmitter. PKC facilitates the release of dopamine (1). Regulation of long-
term changes in gene and neuronal plasticity is another important role of PKC (2, 
3). The pathway of PKC signals regulates the morphology of dendritic branches (4).
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PKC activity and change in platelets of patients with 
mood disorder is in response to protein, which increases 
the percentage of response in patients with mania, 
besides it is reduced in patients treated by lithium (5).
In rodents, PKC stimulation caused by cocaine stimulus 
makes the excitation of manic symptoms. On the other 
hand, the inhibition of PKC activity by lithium and 
valproate results in the reversal of the manic symptoms 
(6, 7). Amphetamines create manic-like behaviors in 
rodents through the effect on PKC and phosphorylation 
of GAP.43 (playing a role in the release of dopamine 
neurotransmitter) (8-10). The use of lithium, valproate 
and tamoxifen inhibit the increase of amphetamine-
induced activity (11).
Since the late 1990s, some drugs have been made based 
on the activity of PKC inhibition, while the mandatory 
characters to test such drugs in humans include: having 
the ability for PKC inhibition in areas of the brain 
involved in the mood disorder, evaluating this ability in 
more than an animal model, passing easily from Blood-
Brain Barrier (BBB) and tolerating the drug absorption. 
The best acceptable candidate with PKC inhibitory 
feature that meets the above characters is Tamoxifen 
(12). Tamoxifen is a synthetic anti-estrogen drug used 
for the treatment of breast cancer (12) and the prevention 
of osteoporosis (13). Due to the lack of metabolic and 
neurological side effects, compared to antipsychotic 
drugs, it is a good alternative in the treatment of acute 
mania (14). Drugs recognized to have interact with 
tamoxifen are 2D6 and P150 drugs such as paroxetine, 
sertraline and duloxetine (15) and sodium valproate, Plus 
phenytoin and carbamazepine (16). Early and before 
maturity onset of a bipolar disorder, usually becomes 
chronic and appears without specific periods and with 
high rate of mixed mania (17). The disease is comorbid 
in onset, worsened by other group of disorders (18) and 
at an increasing rate of comorbidity (19). Therefore, an 
appropriate, timely, effective and low risk treatment is 
essential for bipolar disorder in children. However, there 
are a few drug-controlled studies in this field (20). Short-
term studies on clinical samples in America showed that 
early-onset of Bipolar I disorder is associated with slow 
response rate to treatment, persistent mood swings, high 
recurrence rate, high risk of attempted suicide and severe 
psychosocial disorders (21). Therefore, an aggressive 
treatment of mania and prevention of manic episodes 
can minimize the risk of manic-depressive disorders 
(22). However, intolerance to some side effects such as 
metabolic disorders and overweight are other problems 
that require a special attention and cause some limitations 
to use of these drugs (23). Prevention of recurrence 
plays an important role in the treatment of bipolar 
disorder. The primary objective of recent advanced 
treatment methods is control of the acute phase of the 
disorder before advancing into the chronic stage. This 
objective can be achieved by the use of available anti-
mania, antipsychotic and anticonvulsants drugs. With 
the exception of lithium, these three categories of drugs 
have no priority one over the other (24). Furthermore, 
no interaction has been reported between tamoxifen 
and lithium (25). Anti-manic drugs such as lithium and 
valproate have influence over PKC (26).
There are some reports concerning the effect of tamoxifen 
in treating bipolar disorder in adults. However, there was 
no controlled study to evaluate the effect of tamoxifen in 
children and adolescents with bipolar disorder (8, 27).
Studies on children who suffered from desmoid 
fibromatosis gynecomastia (27) and low-grade brain 
gliomas (28) and who were on tamoxifen therapy up 
two years reported no serious complications. This has 
paramount importance because similar drugs with 
appropriate doses that are used in adults can work for 
children and adolescents (29). Thus, prompt treatment 
of manic episodes and preventing the occurrence of 
chronic course of the disorder and possible side effects 
of some anti-manic drugs such as valporates and second 
generation, antipsychotics starting from childhood is 
vital. 
This study was aimed at measuring the effect of 
tamoxifen as an adjuvant of lithium in reducing the rate 
of symptoms of mania in children as well as adolescents 
with mood disorder.
Materials & Methods
This randomized, double-blinded clinical trial registered 
in www.irct.ir with the code of IRCT201410126418N3, 
was conducted on nine to 20 yr old patients with the 
diagnosis of acute mania hospitalized at Al-Zahra 
University Hospital-Psychiatric Ward, Isfahan, Iran. 
The total sample size was 44 patients of which 22 were 
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assigned in the treatment group (receiving tamoxifen 
+ lithium) and the remaining 22 in the control group 
(receiving placebo+ lithium). 
Written consent was obtained from the guardian or parent 
of each patient after explaining the methods and aims 
of the performance. In addition, the therapeutic method 
was verbally explained the study participants based on 
their level of understanding and developmental stage. 
This study has been approved by ethical committee of 
Isfahan University of Medical Sciences with the code 
of 393501.
The inclusion criteria for the study subjects were the age 
range of 9-20 yr old, the diagnosis of bipolar disorder 
based on K-SADS interview, the Young Mania Rating 
Scale (YMRS) score of above 20, cutting or not taking 
any medication that can affect the mind for at least 2 
weeks prior to the study, independence from any narcotic 
and psychotropic drugs for one month before the study 
had begun, IQ score of greater than 70 and no major 
nervous and physical diseases such as epilepsy.
Lack of desire to continue in the study and the creation 
of intolerable side effects were the exclusion criteria.
Instruments for data collection:
1. The questionnaire of demographic characteristics 
including age and education level 
2. K-SADS Semi-structured interview
Diagnosis of the bipolar disorder, schizophrenia, 
and its type and episode was performed prior to 
treatment using K-SADS interview. The reliability 
and validity of the Persian version for assessment 
and diagnosis of psychiatric disorders in children 
have been reported as accepted (30).
3. The questionnaire of Young Mania Rating Score 
(YMRS) is a measure filled by a physician 
after interviewing a patient, parents and if 
possible, employees in the psychiatric ward. This 
questionnaire is made up of 11 items which are 
scored in 4 levels and for each level a definition for 
that item has been provided. The scores ranged from 
zero to 6. The reliability of the test has been reported 
in the range of 0.41 to 0.85 and its validity is 0.89 
compared to the Patterson Mania and 0.88 compared 
to the Total Mania Rating Tests. The cut-off point 
for diagnosing manic disorder is a score of above 
20. This test enables to differentiate bipolar disorder 
from Attention Deficit-Hyperactivity Disorder 
(ADHD) and is to some extent sensitive to treatment 
with mood stabilizers (31).
4. Maria Kovacs’s Child Depression Inventory (CDI): 
is like Beck’s Depression inventory and is leveled 
as zero, 1 and 2. The range of scores is from zero to 
54 and the cut-off and diagnosis point of depressed 
patients is a score of more than 20. In order to 
measure the validity, Concurrent validity measure of 
CDI scale by teachers has shown a score of 0.193, 
which was significant (32).
5. Table of side effects (33)
Somnolence during day, morning Somnolence, 
constipation, dizziness, fatigue, restlessness, tremor, 
increasing appetite, loss of appetite, blurred vision, 
diarrhea, dry mouth, nervousness
Based on randomized blocks, patients were divided 
into two equal groups that placebo+ lithium was 
administered to one group, while tamoxifen + lithium 
were administered to the other group. The study 
subjects were given 300 mg dose of lithium on the first 
day. Based on the patient’s tolerance level and weekly 
monitoring for its serum level, the dose was increased 
to 0.8-1.1 mg/l. Again, tamoxifen was started with daily 
standard-dose for children, about 20 mg, and increased 
to a maximum of 40 mg/d (33).
Patients of developed insomnia or agitation were 
managed with lorazepam at a starting dose of 1 mg to 
4 mg for the first four days of hospitalization and then, 
the dose for the following days was reduced to 2 mg. 
Placebo, made up of sucrose, was started alone once a 
day in the control group receiving lithium and it was 
increased to twice a day. The questionnaires for YMRS, 
CDI and drug side effects were filled before intervention 
and in the first, second and third weeks.
Response to treatment was evaluated at 50% reduction 
in the rate of YMRS (30), using SPSS version 18 
(Chicago, IL, USA). Age and sex were controlled for 
the ANCOVA and the changes in the CDI and YMRS 
scores in the first, second and third weeks of study were 
compared between the intervention and control groups.
Results
Figure 1 shows the trend of estimated marginal means 
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over the follow-up period of the study. Initially, the 
basic assessments were completed using YMRS and 
CDI questionnaire for 65 study participants. The 
subjects were randomly assigned to the treatment group 
(tamoxifen with lithium) or control group (placebo 
with lithium) and were followed for three weeks. There 
was no statistically significant difference in age, sex, 
and education level at baseline of the two groups. The 
mean age of the participants in the tamoxifen-lithium 
group was 13.8 yr with standard deviation (SD) of ± 
2.1 yr and that of the placebo-lithium group was 14.5 
± 1.9 SD yr. From 10 (45.5%) males and 12 (54.5%) 
females there were 4 patients in the group receiving 
tamoxifen and from 7 males and 15 females, 8 in the 
group receiving placebo that were excluded from the 
study due to severe aggressive behaviors, aggressive and 
serious suicidal thoughts and refusal to eat. Therefore, 
Electro Convulsive Therapy (ECT) was started for 
them. From participants 8 patients were excluded due 
to lack of cooperation on taking drug and finally, 44 
children (17 males and 27 females) stayed in the plan. 
At the beginning of the study, all the participants had the 
YMRS score of above 20. While on the CDI score, 55% 
of the patients had score of less than 20. That means the 
patients who participated in the study were composed 
of those having acute and mixed stages of mania. There 
was no statistically significant difference in YMRS 
score at baseline between the two groups. Because 
there was a significant difference in CDI score among 
the participants at baseline, the role of CDI score was 
controlled in the analysis. At the end of the first, second 
and third weeks of the study, there were statistically 
significant (P <0.05) differences within YMRS and CDI 
groups and statistically significant (P <0.05) differences 
between the treatment and control groups (Table 1).
The effect of follow-up time in four steps (at baseline and 
the first, second and third weeks), the difference between 
the intervention and control groups and in addition to the 
interaction between these two groups with the follow-up 
period is summarized in Table 2. There was no statistically 
significant difference (F3 and 37=2.4; P = 0.81) between 
follow-up periods (follow-up periods at baseline and at 
the end of first, second and third weeks). However, there 
was a statistically significant difference (F1 and 39= 3.4; 
P=0.001) between the treatment (tamoxifen + lithium) 
and the control  (placebo+ lithium) groups  (Figure 1, 2 ).
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Fig 1. Covariates appearing in the model are evaluated 
at the following values: Age=14.5±1.9 (yr)
With regard to Table 3, there was no statistically 
significant difference (F3 and 39 = 0.602; P= 0.67) 
between follow-up periods, while a significant difference 
(F1 and 41= 26.6; P = 0.001) was identified between the 
intervention and control groups.
Fig 2. Covariates appearing in the model are evaluated 
at the following values:
Age=14.5±1.9 (yr)
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The mean differences in YMRS scores in the treatment 
and control groups between baseline and end of the first 
week, between ends of the first and the second weeks 
and ends of the second and the third weeks were 8.5, 5.3 
and 3.9, respectively. After the first week, 10 (45.5%) 
participants in the treatment group and 2 (9.1%) among 
the control group, showed 50% reduction in YMRS 
score and there was a statistically significant difference 
(P = 0.007) between these two groups. At the end of the 
second week, the YMRS score of 19 (86.4%) participants 
in the treatment group and 7(31.8%) participants in the 
control group was less than 50% and the difference in 
these scores was statistically significant (P < 0.001). 
Besides, of 22 (100%) participants in the treatment group 
and 12 (54.5%) in the control group had less than 50% 
reduction in YMRS scores at the end of the third week. 
This difference was statistically significant (P < 0.001). 
In addition, the mean difference in CDI score between 
the treatment and control groups at baseline and the end 
of the first week, end of the first week and end of the 
second week and end of the second week and end of the 
third week were 3.5, 1.5, 1.9 respectively. The symptom 
of mania among the treatment group was significantly 
controlled while the symptoms of depression were not 
significantly controlled. In the control group, there 
was no significant difference between YMRS and CDI 
scores in during the follow-up period. Out of the 13 
participants who developed side effects, eight of them 
were from the control group while only two participants 
in the treatment group developed side effects. The 
remaining three participants reported to have developed 
dry mouth and more of them were in from the treatment 
group. Generally, a statistically significant difference 
(P = 0.009) in relation to side effect development was 
observed between the treatment and control groups.
Discussion
In this clinical trial, the addition of tamoxifen to lithium 
resulted in an increased rate of clinical improvement, 
especially in the first week of treatment. A significant 
decrease in YMRS and slight decline in CDI scores were 
observed.
Treatment with 40 mg tamoxifen per day is well tolerated 
in children and there were no serious side effects 
and complications observed except dry mouth. The 
efficiency of tamoxifen in reducing manic symptoms in 
this study supports the hypothesis that PKC plays a great 
role in the treatment of mania. The effects of tamoxifen 
on central nervous system are complex and appear to 
be a serotonergic system antagonist. However, it has 
no stimulatory effects in cholinergic and adrenergic 
systems (31, 32).
In another study, maniac symptoms were created in mice 
by injecting amphetamine in which the symptoms were 
controlled through injecting tamoxifen for 14 days and 
it seemed that tamoxifen had controlled dysfunction in 
hippocampus and frontal area (33). The use of tamoxifen 
in Kun-Albright syndrome in children has been approved 
(34). In a study on 7 boys with precocious puberty treated 
by tamoxifen with the dose of 10-20 mg for 2 years, no 
side effect was reported (35).
Another study conducted on 59 patients aged between 
10-18 yr with desmoid fibromatosis treated with a high 
dose of tamoxifen for two years helped to control the 
underlying diseases and reported no specific side effects 
(36). In a study on 38 adolescents with gynecomastia of 
puberty period at the age group of 14.6 years treated by 
tamoxifen with the dose of 40 mg for 3 and 9 months, 
no specific side effects were reported; however, the 
underlying disease was controlled (37). In a study on 14 
children under 14 year-old with the diagnosis of low-
grade brain gliomas treated by tamoxifen with the dose 
of 20 mg for one year, it operated well without specific 
side complication in the control of gliomas (38). In 5 
studies on adults, the effect of tamoxifen in the decrease 
of symptoms of mania was is consistent with our results; 
however, no study was found on the effect of tamoxifen 
on the mood of children. In a single blind study on 7 
subjects in the age group of 18-65 yr old (5 females and 
2 males), tamoxifen could have a good performance in 
the treatment of acute mania (39). Tamoxifen only with 
the dose of 20-40 mg was tolerated for 15 days well (39). 
The anti-mania effect of tamoxifen on 51 women was 
compared with that of medroxy progesterone acetate 
for 4 weeks and the anti-mania effect of tamoxifen with 
the dose of 80 mg per day was not attributed to its anti-
estrogenic effects, and it was resulted from the blocks of 
receptors of protein kinase C (40). In another study for 
35.4±7.8 years old participanrs (41) and in the study on 
the age group of 18-65 yr old (42), as monotherapy with 
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a high dose (140 mg per day (40) and 80 mg per day 
(41), tamoxifen was used to treat patients with bipolar 
disorder by current or mixed mania episode for three 
weeks. They also evaluated the effect of tamoxifen on 
other symptoms such as depression and psychosis. Both 
above-mentioned studies showed the high ability of 
tamoxifen as a potent inhibitor of PKC to improve the 
symptoms of mania in which the psychotic symptoms 
was controlled too (41, 42). However, in Hamilton 
Rating Scale for Depression (HRSD), there was no 
significant change in comparison with placebo (41, 
42). The combined treatment of lithium with tamoxifen 
led to a clear mood stability and even the control of 
symptoms of psychosis in bipolar disorder (43). In the 
present study, maximum recovery time and reduction 
in YMRS score were observed in the first week. In 
addition, in the mixed stage of mania cases, CDI score 
was dropped by controlling the underlying disease. In 
none of the participants in treatment group, depression 
was not developed following the use of tamoxifen and 
this is consistent with the findings of studies on adult 
patients with bipolar disorder or current or mixed mania 
episode (40, 43).
The development of depression symptoms were usually 
reported following the long-term use of tamoxifen and in 
patients who had an innate potential to depression (44). 
In a study on 2943 patients with breast cancer treated 
by prolonged monotherapy with tamoxifen with the 
dose of 80 mg, the incidence of New-onset depression in 
tamoxifen recipients was not significant (45). However, 
it seems that a short-term treatment (three weeks) with 
the low-dose of tamoxifen in patients with bipolar 
disorder not only causes the induction of depression but 
also controls the symptoms of depression in the mixed 
cases through the control of acute symptoms of the 
disease (24).
No subject left the study due to the side effects of the 
drug and only dry mouth in the tamoxifen group was 
more common than that in the placebo group. The 
present study is pioneer in the investigation of the effect 
of tamoxifen, which showed the effect on acute phase of 
the disorder is consistent with the similar results of the 
disorder in adults (20, 22, 38, 40).
However, the low number of studied samples, lack of 
examining associated disorders as comorbidity with 
bipolar disorder including psychosis as well as the lack 
of investigation drug effect alone (monotherapy with 
tamoxifen) are among the limitations of the study. It is 
noted that tamoxifen has been effective as monotherapy 
(41-42) and in improving the prognosis of psychosis 
among adults (43).
In conclusion, the addition of tamoxifen to lithium 
showed a significant difference between the treatment 
and control groups in reducing the symptoms of mania 
and depression. 
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Table 1. Within group comparison of CDI and YMRS scores at baseline and at the end of first, second and third 
weeks of follow up the study participants with bipolar disorder treated by tamoxifen or placebo
Variable Tamoxifen -Lithium Lithium -Placebo P. Value 
Mean of YMRS* SD-(Base)







Mean of YMRS SD-(First Week)







Mean of YMRS SD-(Second Week)







Mean of YMRS SD-(Third Week)







*Young Mania Rating Scale (YMRS), # Children Depression Inventory
Table 2. Results of covariance with replicated test score with the result of mania score in the study population 
controlling age and sex 
Variables F value DF P. value




The interaction of follow up duration and 
intervention groups
3.25 3.37 0.032
Table 3. Results of the analysis of covariance (ANCOVA) with replication with the outcome of depression score in 
the population studied controlling age and sex 
Variables F value DF P. value




The interaction of follow up duration and 
intervention groups
0.592 3.39 0.624
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Table 4. Comparison of side effects in the two studied groups 
Side Effect Lithium+Tamoxifen Lithium+Placebo P. value
Drowsiness 0.22 2.22 0.488
Vertigo 0.22 2.22 0.488
Shivering 1.22 4.22 0.254
Overeating 0.22 1.22 1
Anorexia 0.22 2.22 0.488
Blurred vision 1.22 2.22 1
Fatigue 0.22 1.22 1
Agitation 1.22 0.22 1
Xerostomia 7.22 0.22 0.009
Anxiety 0.22 2.22 0.488
Diarrhea 0.22 0.22 1
Constipation 0.22 0.22 1
Low body movement 0.22 0.22 1
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